[Hypolipidaemic agents (author's transl)].
作者信息
Tillement J P, Albengres E, Choisy H, Millart H
出版信息
Nouv Presse Med. 1980 Oct 30;9(40):2947-50.
PMID:7443428
Abstract
Since clofibrate was discovered, a number of compounds have been made available for the treatment of hyperlipoproteinaemias. Their principal pharmacological and therapeutic properties are summarized in this paper. Other compounds are now under pre-clinical or clinical studies, including probucol which is reviewed in this issue.
摘要
相似文献
1
[Hypolipidaemic agents (author's transl)].
Nouv Presse Med. 1980 Oct 30;9(40):2947-50.
2
[Mechanism of action of drugs affecting lipid metabolism].[影响脂质代谢的药物作用机制]
Minerva Med. 1975 Oct 6;66(66):3458-68.
3
[Biochemical and experimental aspects of the lipid-lowering drugs pharmacology (author's transl)].
Sem Hop. 1979;55(41-42):1947-55.
4
[Pharmacological treatment of primary hyperlipoproteinemia].[原发性高脂蛋白血症的药物治疗]
Pol Tyg Lek. 1976 Feb 16;31(7):289-91.
5
The primary hyperlipoproteinemias.原发性高脂血症。
J Ky Med Assoc. 1974 Dec;72(12):658-62.
6
[Antilipemic agents available after the ban on clofibrate: clinical-pharmacological view].
Fortschr Med. 1979 Apr 19;97(15):695-6, 698.
7
[Therapeutic orientation in the hyperlipidemias].
Arq Bras Cardiol. 1979 Sep;33(3):207-15.
8
The effect of hypolipidemic drugs on plasma lipoproteins.
Annu Rev Pharmacol Toxicol. 1977;17:499-510. doi: 10.1146/annurev.pa.17.040177.002435.
9
[Treatment of hyperlipoproteinemias (author's transl)].
G Ital Cardiol. 1974;4(3):332-40.
10
Hyperlipidemia: reducing the chances of cardiovascular disease.
Geriatrics. 1984 Jul;39(7):99-100, 103-4,108-9 passim.
Zotero 插件